Unresolved antiretroviral treatment management issues in HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 2, 2012, Pages 161-169

  Heidari, Shirin ^a   Mofenson, Lynne M ^b   Hobbs, Charlotte V ^b   Cotton, Mark F ^c   Marlink, Richard ^d,e   Katabira, Elly ^f  

^a UNAIDS   (Switzerland)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^f MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

Antiretroviral; Childhood growth and development; Drug complications; HIV infected infants; Malaria; Malnutrition; Tuberculosis

Indexed keywords

ABACAVIR; AMODIAQUINE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMETHER; BCG VACCINE; BENFLUMETOL; COTRIMOXAZOLE; CYCLOSERINE; DIDANOSINE; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE;

ANEMIA; BODY WEIGHT; BONE DEVELOPMENT; BONE MINERAL; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHILD NUTRITION; CHILDHOOD DISEASE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DIABETES MELLITUS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER TOXICITY; MALARIA; MALNUTRITION; METABOLIC DISORDER; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; VITAMIN D DEFICIENCY; WORLD HEALTH ORGANIZATION;

EID: 85027922520     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182427029     Document Type: Review

References (101)

1. Ciaranello AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009; 49: 1915-1927.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector-Progress Report 2010. Geneva, Switzerland: UNAIDS; 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241500395-eng.pdf. Accessed January 3, 2011.
3. World Health Organization (WHO). Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2009. WHO. Geneva, Switzerland; 2009. Available at: http://www. who.int/hiv/pub/tuapr-2009-en.pdf. Accessed August 4, 2010.
4. Violari A, Cotton MF, Gibb DM, et al; and CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359: 2233-2244.
5. World Health Organization (WHO). Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting. Geneva, Switzerland: WHO; 2008. Available at: http://www.who.int/hiv/pub/paediatric/WHO-Paediatric- ART-guideline-rev-mreport-2008.pdf. Accessed September 10, 2010.
6. World Health Organization (WHO). Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Geneva, Switzerland: WHO; 2010. Available at: http://www.who.int/entity/hiv/-pub/paediatric/infants2010/ en/index.html. Accessed September 10, 2010.
7. Willen EJ. Neurocognitive outcomes in pediatric HIV. Ment Retard Dev Disabil Res Rev. 2006; 12: 223-228. (Pubitemid 44646332)
8. Patel K, Ming X, Williams PL, et al; and International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009; 23: 1893-1901.
9. Lindsey JC, Malee KM, Brouwers P, et al; and PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007; 119: E681-E693. (Pubitemid 46407543)
10. Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011; 57: 290-296.
11. Laughton B, Springer P, Grove D, et al. Longitudinal development profile of children from low socio-economic circumstances in Cape Town, using the 1996 Griffiths mental development scales. SAJCH. 2010; 4: 78-83.
12. Abubakar A, Van Baar A, Van de Vijver FJ, et al. Paediatric HIV and neurodevelopment in sub-Saharan Africa: a systematic review. Trop Med Int Health. 2008; 13: 880-887. (Pubitemid 351813515)
13. Brahmbhatt H, Boivin M, Ssempija V, et al. Impact of long-term ARV use on neurologic outcomes among HIV-positive children aged 0 to 7 years. Presented at: 6th IAS Conference on HIV Treatment, Pathogenesis and Prevention; July 17-20, 2011; Rome, Italy. Abstract TuPE 211.
14. Van Rie A, Dow A, Mupuala A, et al. Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2009; 52: 636-642.
15. Puthanakit T, Aurpibul L, Louthrenoo O, et al. Poor cognitive functioning of school-aged children in Thailand with perinatally acquired HIV infection taking antiretroviral therapy. AIDS Patient Care STDS. 2010; 24: 141-146.
16. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006; 118: E711-E718. (Pubitemid 46089998)
17. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005; 116: E846-E854. (Pubitemid 46056464)
18. Zuccotti G, Viganò A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010; 46: 1633-1638.
19. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010; 24: 687-696.
20. Rosso R, Vignolo M, Parodi A, et al. Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. AIDS Res Hum Retroviruses. 2005; 21: 927-932. (Pubitemid 41785778)
21. Stephensen CB, Maquis GS, Kruzich LA, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006; 83: 1135-1141. (Pubitemid 44713115)
22. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010; 15: 425-429.
23. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011; 96: 3160-3169.
24. Cervia JS, Chantry CJ, Hughes MD, et al; For the PACTG 1010 Team. Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy. Pediatr Infect Dis J. 2010; 29: 1118-1122.
25. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005; 40: 161-168. (Pubitemid 41395714)
26. Rhoads MP, Lanigan J, Smith CJ, et al. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011; 57: 404-412.
27. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS. 2009; 23: 661-672.
28. Ramalho LC, Gonçalves EM, de Carvalho WR, et al. Abnormalities in body composition and nutritional status in HIV-infected children and adolescents on antiretroviral therapy. Int J STD AIDS. 2011; 22: 453-456.
29. Innes S, Eagar R, Edson C, et al. Prevalence, DEXA differences and risk factors for lipoatrophy among pre-pubertal African children on HAART. Presented at: 3rd International Workshop on HIV Pediatrics; July 15-16, 2011; Rome, Italy. Abstract PP-10.
30. Jacobson DL, Williams P, Tassiopoulos K, et al. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr. 2011; 57: 413-420.
31. Shiau S, Arpadi S, R, Strehlau R, et al. Body composition and metabolic abnormalities of perinatally HIV-infected children in South Africa on long-term ARV treatment. Presented at: 3rd International Workshop on HIV Pediatrics; July 15-16, 2011; Rome, Italy. Abstract O-2.
32. Homkham N, Akarathum N, Thanasiri P, et al. Association between hyperlipidemia and high plasma efavirenz levels in children in the PHPT observational cohort, Thailand. Presented at: 3rd International Workshop on HIV Pediatrics; July 15-16, 2011; Rome, Italy. Abstract P-48.
33. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002; 360: 985.
34. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis. 2009; 48: 108-114.
35. Schaaf HS, Krook S, Hollemans DW, et al. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2005; 24: 685-691. (Pubitemid 41140950)
36. Martinson NA, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009; 13: 862-867.
37. Braitstein P, Nyandiko W, Vreeman R, et al. The clinical burden of tuberculosis among human immunodeficiency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment. Pediatr Infect Dis J. 2009; 28: 626-632.
38. Walters E, Cotton MF, Rabie H, et al. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr. 2008; 8: 1.
39. Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitorbased antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010; 201: 1121-1131.
40. Zanoni BC, Phungula T, Zanoni HM, et al. Impact of tuberculosis cotreatment on viral suppression rates among HIV positive children initiating HAART. AIDS. 2011; 25: 49-55.
41. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007; 196(suppl 1): S63-S75. (Pubitemid 47206086)
42. European Medicines Agency (EMA). Norvir. European Public Assessment Report. Annex I. Summary of Product Characteristics. London, United Kingdom: EMA; 2011. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000127/WC500028728.pdf. Accessed September 22, 2011.
43. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicinbased treatment for tuberculosis. Antivir Ther. 2011; 16: 417-421.
44. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008; 47: 566-569. (Pubitemid 351442016)
45. Elsherbiny D, Ren Y, McIlleron H, et al. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol. 2010; 66: 1017-1023.
46. Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011; 6: e17273.
47. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusteddose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48: 1553-1560. (Pubitemid 38544359)
48. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol. 2010; 6: 55-68.
49. Oudjik JMMH, Mulenga V, Chintu C, et al. Pharmacokinetics of nevirapine in young children during combined ART and rifampicincontaining antituberculosis treatment. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract LBPeB10.
50. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009; 50: 439-443.
51. International Union Against Tuberculosis and Lung Disease (The Union) and World Health Organisation. Guidance for National Tuberculosis and HIV Programmes on the Management of Tuberculosis in HIV-Infected Children: Recommendations for a Public Health Approach. The Union. Paris, France, 2010. Available at: http://www. theunion.org/index.php/resources/scientific- publications/index.php?id=630&cid=759&fid=57&task= download&option=com-flexicontent &Itemid=70&lang=en. Accessed September 22, 2011.
52. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009; 23: 1097-1107.
53. Orikiiriza J, Bakeera-Kitaka S, Musiime V, et al. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS. 2010; 24: 2009-2017.
54. Rabie H, Violari A, Duong T, et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011; 15: 1194-1200.
55. Pensi T, Banerjee T, Haemal A, et al. Effect of simultaneous therapy on the survival of HIV-tuberculosis coinfected paediatric patients. Presented at: 2nd International Workshop on HIV Pediatrics; July 16-17, 2010; Vienna, Austria.
56. Yotebieng M, Van Rie A, Moultrie H, et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS. 2010; 24: 1341-1349.
57. Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatr Respir Rev. 2011; 12: 22-26.
58. Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis. 2010; 10: 51-59.
59. DjimdéAA, Doumbo OK, Traore O, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003; 69: 558-563. (Pubitemid 38248261)
60. Steiner K, Myrie L, Malhotra I, et al. Fetal immune activation to malaria antigens enhances susceptibility to in vitro HIV infection in cord blood mononuclear cells. J Infect Dis. 2010; 202: 899-907.
61. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005; 365: 233-240. (Pubitemid 40138017)
62. Laufer MK, van Oosterhout JJ, Thesing PC, et al. Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. Am J Trop Med Hyg. 2007; 77: 627-632. (Pubitemid 351844282)
63. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004; 364: 1428-1434. (Pubitemid 39370718)
64. Otieno RO, Ouma C, Ong'echa JM, et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS. 2006; 20: 275-280.
65. van Eijk AM, Ayisi JG, Ter Kuile FO, et al. Malaria and human immunodeficiency virus infection as risk factors for anemia in infants in Kisumu, western Kenya. Am J Trop Med Hyg. 2002; 67: 44-53. (Pubitemid 35034319)
66. Imani PD, Musoke P, Byarugaba J, et al. Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a casecontrol study. BMC Pediatr. 2011; 11: 5.
67. Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis. 2009; 49: 336-343.
68. Newton CR. Interaction between Plasmodium falciparum and human immunodeficiency virus type 1 on the central nervous system of African children. J Neurovirol. 2005; 11(suppl 3): 45-51.
69. World Health Organization (WHO). Guidelines for the Treatment of Malaria. 2nd ed. Geneva, Switzerland: WHO; 2010. Available at: http://whqlibdoc.who.int/ publications/2010/9789241547925-eng.pdf.Accessed January 26, 2011.
70. Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005; 19: 995-1005. (Pubitemid 40961139)
71. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008; 46: 985-991. (Pubitemid 351589861)
72. Falade C, Makanga M, Premji Z, et al. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005; 99: 459-467. (Pubitemid 40521344)
73. Katrak S, Gasasira A, Arinaitwe E, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J. 2009; 8: 272.
74. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009; 51: 424-429.
75. van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg. 1999; 61: 964-967. (Pubitemid 30084122)
76. Novartis Pharmaceuticals Corporation. Coartem. Highlights of Prescribing Information. Novartis: East Hanover, NJ; 2010. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/coartem.pdf. Accessed October 11, 2010.
77. Fehintola FA, Akinyinka OO, Adewole IF, et al. Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab. 2011; 12: 51-56. Review.
78. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to interaction between artesunate plus amodiaquine and efavirenz. Clin Infect Dis. 2007; 44: 889-891. (Pubitemid 46365323)
79. World Health Organization Guidelines for the Treatment of Malaria. 2nd ed. WHO: Geneva, Switzerland. Available at: http://whqlibdoc.who.int/ publications/2010/9789241547925-eng.pdf. Accessed December 15, 2011.
80. Laufer MK, Plowe CV. Cotrimoxazole prophylaxis and malaria in Africa: have the important questions been answered? Am J Trop Med Hyg. 2006; 75: 373-374. (Pubitemid 46941292)
81. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ. 2011; 342: D1617.
82. Gasasira AF, Kamya MR, Ochong EO, et al. Effect of trimethoprimsulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010; 9: 177.
83. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprimsulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007; 21: 2059-2066. (Pubitemid 47462155)
84. Hobbs CV, Voza T, Coppi A, et al. HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis. 2009; 199: 134-141.
85. Parikh S, Gut J, Istvan E, et al. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 2005; 49: 2983-2985. (Pubitemid 40917621)
86. Skinner-Adams TS, McCarthy JS, Gardiner DL, et al. Antiretrovirals as antimalarial agents. Infect Dis. 2004; 190: 1998-2000. (Pubitemid 39564706)
87. Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother. 2011; 55: 5073-5077.
88. Heikens GT. How can we improve the care of severely malnourished children in Africa? PLoS Med. 2007; 4(2): e45.
89. Oshikoya KA, Senbanjo IO. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab (Lond). 2009; 6: 50.
90. Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010; 66: 1025-1035.
91. Heikens GT, Bunn J, Amadi B, et al. Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. Lancet. 2008; 371: 1305-1307. (Pubitemid 351491320)
92. Prendergast A, Bwakura-Dangarembizi MF, Cook AD, et al. Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. AIDS. 2011; 25: 951-956.
93. Naidoo R, Rennert W, Lung A, et al. The influence of nutritional status on the response to HAART in HIV-infected children in South Africa. Pediatr Infect Dis J. 2010; 29: 511-513.
94. Musoke PM, Mudiope P, Barlow-Mosha LN, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010; 10: 56.
95. Banerjee T, Pensi T, Banerjee D, et al. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. Ann Trop Paediatr. 2010; 30: 27-37.
96. Bandyopadhyay A, Bhattacharyya S. Effect of pre-existing malnutrition on growth parameters in HIV-infected children commencing antiretroviral therapy. Ann Trop Paediatr. 2008; 28: 279-285.
97. Pandian PGDN, Chandran P, Kandasamy C, et al. Persistence of stunting after HAART in HIV-infected children in south India. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, US Abstract 847.Available at: http://www.retroconference.org/ 2010/Abstracts/36912.htm. Accessed September 10, 2010.
98. Weigel R, Phiri S, Chiputula F, et al. Growth response to antiretroviral treatment in HIV-infected children: a cohort study from Lilongwe, Malawi. Trop Med Int Health. 2010; 15: 934-944.
99. Fergusson P, Chinkhumba J, Grijalva-Eternod C, et al. Nutritional recovery in HIV-infected and HIV-uninfected children with severe acute malnutrition. Arch Dis Child. 2009; 94: 512-516.
100. Hughes SM, Amadi B, Mwiya M, et al. CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. Pediatrics. 2009; 123: E347-E351.
101. International AIDS Society (IAS). Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children. Geneva, Switzerland: IAS; 2010. Available at: http://www.iasociety. org/Default.aspx?pageId=396. Accessed October 11, 2010.